Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Selected immunohistochemical features of conventional renal cell carcinomas coexpressing P53 and MDM2.

Polish journal of pathology : official journal of the Polish Society of Pathologists - 1 Jun 2014

Hejnold M, Dyduch G, Białas M, Demczuk S, Ryś J, Chłosta P, Szopiński T, Okoń K

Abstract excerpt

Renal clear cell carcinoma (CCRCC) is an aggressive tumor for which new prognostic factors are needed. It has been suggested that CCRCCs co-expressing P53 and MDM2 could represent a special subgroup; therefore the aim of this study was to explore their immunohistochemical features. The material studied consisted of 470 cases of CCRCC. Immunohistochemistry for MDM2, P53, Ki-67, VEGF-A, VEGF-C, VEGF-D, GLUT1, CA9,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biopsy
Share to Carcinoma, Renal Cell

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Kidney Neoplasms

Share to Neoplasm Grading

Share to Neoplasm Staging

Share to Predictive Value of Tests

Share to Proto-Oncogene Proteins c-mdm2

Share to Tissue Array Analysis

Source

Identifiers

PMID: 25119170
DOI: 10.5114/pjp.2014.43960

Genes

MDM2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Selected immunohistochemical features of conventional renal cell carcinomas coexpressing P53 and MDM2.PMID 25119170Read ↗

p53 and MDM2 in renal cell carcinoma: biomarkers for disease progression and future therapeutic targets?Semantic proximity Read ↗

[Immunohistochemical characterisation of the main histologic subtypes of epithelial renal tumours on tissue-microarrays. Study of 310 cases].Semantic proximity Read ↗

Combined p53 and MDM2 biomarker analysis shows a unique pattern of expression associated with poor prognosis in patients with renal cell carcinoma undergoing radical nephrectomy.Semantic proximity Read ↗

P53 mutations and other prognostic factors of renal cell carcinoma.Semantic proximity Read ↗

Clinical significance of immunohistochemically detectable p53 protein in renal cell carcinoma.Semantic proximity Read ↗

Immunomorphological characteristics of renal cell carcinoma.Semantic proximity Read ↗

Association of cytokeratin 7 and 19 expression with genomic stability and favorable prognosis in clear cell renal cell cancerSemantic proximity Read ↗

p53 and HER-2 alterations in renal cell carcinoma.Semantic proximity Read ↗

Infrequent p53 gene mutations and lack of p53 protein expression in clear cell sarcoma of the kidney: immunohistochemical study and mutation analysis of p53 in renal tumors of unfavorable prognosis.Semantic proximity Read ↗

Functional and gene expression analysis of the p53 signaling pathway in clear cell sarcoma of the kidney and congenital mesoblastic nephroma.Semantic proximity Read ↗

Immunohistochemical co-expression of c-erbb-2/Neu oncoprotein, altered tumour suppressor (p53) protein, EGF-R and EMA in histological subtypes of infiltrating duct carcinoma of the breast.Semantic proximity Read ↗

Immunophenotypic markers in renal cell carcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.